drugset / Trial / NCT01064440

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

NCT01064440 ↗

Phase 2 Completed 52 enrolled Helixmith Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate whether intramuscular injections of VM202 into the calf is safe and effective in the treatment of critical limb ischemia.

Timeline

Start
2010-07-09
Primary completion
2013-08-05
Completion
2023-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject VM202 Other / unclassified 8 mg Intramuscular
Subject VM202 Other / unclassified 16 mg Intramuscular

Indications